Lung cancer is now the leading cause of cancer deaths in the United States, claiming more lives than several other major ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study, published in the International Journal of Molecular Science ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...

Ten years ago, a discussion in Milan set a demanding project in motion. In a meeting between a biologist and a urologist, one ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...